Empamax M Sustained-release Tablet 12.5/750 mg (Empagliflozin, Metformin)
Empagliflozin L-Proline 15.69mg · Metformin Hydrochloride 750mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
MFDS item code 202501900 · Approved 2025.07.24
Improvement of glycemic control in adults with type 2 diabetes mellitus
This medicine is used to help control blood sugar levels in adult patients with type 2 diabetes, when combined with dietary and exercise therapy. It effectively improves blood sugar when empagliflozin and metformin are administered together. It can also be used cautiously in patients with type 2 diabetes whose blood sugar is not adequately controlled and who have confirmed cardiovascular disease, but clinical trial information should be consulted for caution. This drug is used to enhance blood sugar control and assist in the management of type 2 diabetes.
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin hydrochloride extended-release 2000 mg. This medicine should be taken once daily with the evening meal to reduce gastrointestinal adverse reactions caused by metformin. Patients taking this medicine as 10/1000 mg or 25/1000 mg extended-release tablets should take 1 tablet once daily. Patients taking this medicine as 12.5/1000 mg or 12.5/750 mg extended-release tablets should take 2 tablets together once daily. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. ⦁ For patients whose blood glucose is not adequately controlled with metformin alone or in combination with other medicines such as insulin, the recommended initial total daily dose of this medicine is empagliflozin 10 mg and the patient's current metformin dose. If empagliflozin 10 mg is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg. ⦁ Patients switching from concomitant therapy with empagliflozin and metformin to this medicine should receive their current doses of empagliflozin and metformin. When switching from immediate-release to extended-release metformin, blood glucose control should be closely monitored and the dose adjusted as appropriate. ⦁ When this medicine is used concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). Because dosage adjustment according to renal function is necessary, assessment of renal function is recommended before starting this medicine and periodically thereafter. No dosage adjustment of this medicine is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 60 mL/min/1.73 m2]. In patients with moderate renal impairment [CKD stage 3A, creatinine clearance (CrCl) ≧ 45 mL/min and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≧ 45 mL/min/1.73m2 and < 60 mL/min/1.73m2] who tolerate treatment well and do not have other conditions that may increase the risk of lactic acidosis, this medicine may be used with metformin hydrochloride dose adjustment as follows. - Because the starting dose of extended-release metformin hydrochloride is 500 mg or 750 mg once daily, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000 mg. If creatinine clearance (CrCl) decreases to less than 45 mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45 mL/min/1.73m2, this medicine should be discontinued immediately. In patients aged 75 years and older, renal function and the risk of volume depletion should be considered.
This drug helps lower blood sugar. However, it can rarely cause a hazardous condition known as severe lactic acidosis, so one must be well-informed about this symptom. Lactic acidosis is a condition where there is an excessive buildup of lactic acid in the body, with symptoms including malaise, muscle pain, difficulty breathing, weakness, and abdominal pain. Additionally, this drug may cause hypoglycemia when taken with insulin or sulfonylurea medications, so caution is required. This drug should not be used in patients with moderate to severe renal impairment, acute renal failure, severe infections, or dehydration. It is also not for patients with type 1 diabetes or diabetic ketoacidosis. Administration of this drug should be stopped before and after tests using iodine contrast agents and should only be resumed after confirming normal kidney function. Women who are pregnant or may become pregnant, patients with liver dysfunction, patients with severe heart failure, and patients who are malnourished or in a state of weakness should avoid using this medication. During the duration of this medication, regular kidney function checks are required to ensure there are no abnormalities. If fever, pain, or swelling around the genitals or perineum, or erythema occurs, immediate consultation with a physician is necessary, as this may indicate a serious infection. This drug may cause side effects including hypoglycemia, urinary tract infections, genital infections, increased urination, gastrointestinal disturbances, and symptoms necessitating careful observation. Particularly, elderly patients or those at risk of dehydration should monitor for fluid loss, and excessive alcohol consumption should be avoided while on this medication. Long-term use may also lead to vitamin B12 deficiency, so it is advisable to check serum vitamin B12 levels. It is crucial not to crush or chew the tablets but to swallow them whole, although the casing may appear in stool, which is normal. Lastly, while taking this drug, regular check-ups and strict management of dosage adjustments and side effects per physician's instructions are crucial.
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly closed container to protect it from air and moisture. The storage temperature should be maintained at room temperature between 1 degree and 30 degrees.
Dark yellow oval sustained-release film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Empagliflozin L-Proline 15.69mg · Metformin Hydrochloride 750mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 15.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 15.7mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
(Co., Ltd.) Chong Kun Dang
CombinationEmpagliflozin L-Proline 15.7mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jonggeun Dang Co., Ltd.
CombinationEmpagliflozin L-Proline 6.28mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 6.28mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 6.28mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationEmpagliflozin L-Proline 12.55mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.